Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04845217
Other study ID # 21.0286
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date September 15, 2021
Est. completion date December 2023

Study information

Verified date August 2022
Source University of Louisville
Contact Jenna Warehime, DO
Phone 502-588-7660
Email pepperminttrial@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the use of peppermint oil as a treatment for Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS).


Description:

After being informed about the study and potential risks, all participants will complete validated IC/BPS symptom questionnaires for baseline screening. Once participants meet eligibility requirements and give written informed consent they will be randomized in a 1:1 ratio to peppermint oil (200mg TID) or placebo (also TID). Participants will complete validated IC/BPS questionnaires and follow up surveys over 8 weeks.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 2023
Est. primary completion date June 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Women ages 18-65 years old - Diagnosed with IC/BPS for at least one month prior to study enrollment Exclusion Criteria: - Culture proven urinary tract infection within 1 month of randomization - Gross hematuria - Currently pregnant or breastfeeding - Unable to speak and read English - History of allergic reaction to peppermint, coconut or enteric coating - History of malabsorption syndrome - History of gastroparesis - History of gastric bypass surgery - History of gastrointestinal, genitourinary or pelvic cancer in the last 5 years - History of insulin dependent diabetes - History of active urinary stone disease

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Peppermint oil
Enteric coated peppermint oil taken by mouth three times daily for 8 weeks.
Coconut Oil
Enteric coated coconut oil taken by mouth three times daily for 8 weeks

Locations

Country Name City State
United States Springs Medical Center Louisville Kentucky

Sponsors (2)

Lead Sponsor Collaborator
University of Louisville Integrative Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary O'Leary/Sant questionnaire scores Participant responses to the O'Leary/Sant questionnaire assessing IC/BPS symptoms will be compared at baseline and after starting treatment with peppermint oil. 8 weeks
Primary Pelvic Pain and Urgency/Frequency questionnaire scores Participant responses to the Pelvic Pain and Urgency/Frequency questionnaire assessing IC/BPS symptoms will be compared at baseline and after starting treatment with peppermint oil. 8 weeks
Secondary Urine pH Changes in urine pH on urine dipstick from clinically indicated lab collections at the time of office visits during the study period 8 weeks
Secondary Incidence of urinary tract infections (UTIs) Culture proven UTIs during the study period (>100,000 CFU of a single pathogen) 8 weeks
Secondary Additional IC/BPS Treatments received Number and type of additional IC/BPS each participant undergoes 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT04313972 - IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone Phase 4
Completed NCT03282318 - A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis Phase 2
Completed NCT03463499 - The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients N/A
Completed NCT02898220 - Trans-MAPP II Study of Urologic Chronic Pelvin Pain
Terminated NCT02591199 - Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Phase 2
Completed NCT02247557 - Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis Phase 2
Active, not recruiting NCT01731470 - Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS) N/A
Completed NCT01197261 - OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS) Phase 2
Completed NCT00971568 - Urinary Biomarkers Characteristic to Interstitial Cystitis N/A
Completed NCT00527917 - A Pilot Clinical Investigation of the Efficacy and Safety of Uracyst® Versus Placebo in Patients With Interstitial Cystitis/Painful Bladder Syndrome. Phase 2
Completed NCT00150488 - URACYST® For the Treatment of GAG Deficient Interstitial Cystitis N/A
Recruiting NCT00094874 - Acupuncture for the Treatment of Interstitial Cystitis (IC) Symptoms Phase 3
Terminated NCT00086684 - Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis Phase 4
Completed NCT04401176 - Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome Phase 2
Recruiting NCT05147779 - Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis Phase 1
Suspended NCT04450316 - Low-dose Naltrexone for Bladder Pain Syndrome Phase 2
Completed NCT04010513 - Hypnosis for Bladder Pain Syndrome N/A
Completed NCT05179460 - A Study of Pentosan Polysulfate Sodium and the Development of Pigmentary Maculopathy and Pigmentary Retinopathy
Completed NCT02232282 - Acupuncture for Female IC/PBSyndrome and Its Effect on the Urinary Microbiome: A Randomized Controlled Trial N/A
Completed NCT00546858 - Relationship of Interstitial Cystitis to Vulvodynia N/A